Solving healthcare’s $20 billion superbug problem
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Business Affairs Homepage

Siemens to acquire Corindus Vascular Robotics in $1.1 billion deal Royal currently has a 12.8 percent stake in Corindus

Health Catalyst IPO — The Signify View The industry analysts share their perspective on the announcement

RadNet acquires Nulogix, opens new AI division Will develop applications for image interpretation

Carestream completes sale of IT business to Philips in most countries Now part of Philips in 26 of 38 countries where it operates

Siemens rises above $4 billion in revenue in third quarter Revenue rose by 5.8 percent compared to last year

Siemens diagnostics president to step down, new board member appointed CEO Bernd Montag will assume responsibility of the business unit

Four tips to creating greater efficiencies in your imaging department Insights from the data obtained by Definitive Healthcare

Hospital M&A revenue rose to $11.3 billion in Q2 this year Atrium Health acquiring Wake Forest Baptist Health was most notable

Philips Q2 sales helped by Chinese healthcare spending Sales rose in the U.S. and Europe as well

UnitedHealth Group reported strong second quarter 2019 results, beating expectations Total revenues at $60.6 billion, up eight percent year over year

Solving healthcare’s $20 billion superbug problem

By Evan Jones

Hospitals in the U.S. have an expensive – and deadly – problem. Multi-drug-resistant organisms (MDROs), or superbugs, are common bacteria that have developed a resistance to multiple types of antibiotics, and hospitals across the country are having difficulty identifying, tracking, and treating them.

Story Continues Below Advertisement

New & Refurbished C-Arm Systems. Call 702.384.0085 Today!

KenQuest provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs

The Centers for Disease Control and Prevention (CDC) estimates that in the U.S. alone we face two million illnesses and 23,000 deaths annually, all attributable to MDROs. The cost for managing these hospital-acquired infections, that have so far been reported in nearly every state? More than $20 billion annually.

What’s worse, according to the CDC, it appears as though the superbug issue is only in its infancy. Superbugs are projected to be a bigger killer than cancer by 2050, causing 10 million deaths annually, and further emphasizing the critical need for the development of improved treatment programs. The CDC itself recently announced the U.S. government’s Antimicrobial Resistance (AMR) Challenge, a yearlong effort to accelerate the fight against antimicrobial resistance across the globe, showcasing the immediate concern for this looming healthcare issue. But much work still remains.

A biotech-powered solution?
Sadly, the pipeline for new antibiotic drugs that can combat MDROs is limited. With the lack of new therapeutics and the growing need to protect the efficacy of existing antibiotics, an important weapon in combating superbugs is rapid detection. Rapid molecular technologies for MDRO testing could help identify bacterial infections and guide appropriate patient management decisions earlier, improve infection control programs, and provide hospitals with faster and more targeted antibiotic response that improves patient outcomes and saves money.

In just hours, a combined rapid diagnostic and bioinformatic platform has potential to detect and identify multi-drug resistant pathogens, guide first-line antibiotic therapy more precisely, and locate antibiotic resistant threats throughout healthcare institutions and networks. With these integrated technologies, an antibiotic resistance database specific to institutions is now possible to help inform clinical actions by predicting resistance to specific antibiotics and determining if the antibiotic resistant pathogen is related to pathogens previously detected in the health system. For the first time, we have a rapid solution harnessing the power of genomics and bioinformatics to combat antibiotic resistance proactively and comprehensively. We can better protect patients and our supply of antibiotics from the growing superbug problem.
  Pages: 1 - 2 >>

Business Affairs Homepage

You Must Be Logged In To Post A Comment